Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • The one-trial era: what the FDA’s shift signals for the future of drug development
  • Part three: Regulatory considerations, validation strategies and emerging trends: qPCR/dPCR/ddPCR
  • A single test for multiple diseases

Related tags

antibody Bio-rad biotherapeutics technology
Previous article Next article

Related articles

21 NOV 2018 DIAGNOSTICS
NanoPOTS technology developed to monitor cancer by blood sampling
10 MAR 2011 CHROMATOGRAPHY
One size does not fit all
5 JUL 2022 NEWS
CFX Opus Deepwell system: the latest bioinnovation for real-time PCR
8 JAN 2013 COLLABORATIONS AND MERGERS
Sanofi and Myriad RBM collaborate in diabetes research
6 FEB 2018 BIOMARKERS
Quantitative immunochromatographic test could aid diagnosis of early heart attack and sepsis
25 NOV 2014 NEWS
New rapid test for bloodstream infections developed
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone